Reviewing ANCHIANO THERAP/S (ANCN) and Its Peers

ANCHIANO THERAP/S (NASDAQ: ANCN) is one of 574 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare ANCHIANO THERAP/S to related companies based on the strength of its institutional ownership, earnings, dividends, risk, valuation, profitability and analyst recommendations.

Insider & Institutional Ownership

6.2% of ANCHIANO THERAP/S shares are owned by institutional investors. Comparatively, 46.2% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.8% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for ANCHIANO THERAP/S and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANCHIANO THERAP/S 0 0 3 0 3.00
ANCHIANO THERAP/S Competitors 5030 13987 29043 1061 2.53

ANCHIANO THERAP/S currently has a consensus target price of $14.00, suggesting a potential upside of 230.97%. As a group, “Pharmaceutical preparations” companies have a potential upside of 58.03%. Given ANCHIANO THERAP/S’s stronger consensus rating and higher possible upside, research analysts clearly believe ANCHIANO THERAP/S is more favorable than its rivals.


This table compares ANCHIANO THERAP/S and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ANCHIANO THERAP/S Competitors -1,460.08% -872.05% -29.05%

Earnings & Valuation

This table compares ANCHIANO THERAP/S and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ANCHIANO THERAP/S N/A -$13.28 million -0.81
ANCHIANO THERAP/S Competitors $2.14 billion $227.40 million -3.98

ANCHIANO THERAP/S’s rivals have higher revenue and earnings than ANCHIANO THERAP/S. ANCHIANO THERAP/S is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


ANCHIANO THERAP/S beats its rivals on 7 of the 12 factors compared.


Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Jerusalem, Israel.

Receive News & Ratings for ANCHIANO THERAP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANCHIANO THERAP/S and related companies with's FREE daily email newsletter.